Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse Lewy Body Disease.

Theresa A. Zesiewicz1, Matthew J. Baker, Peter B. Dunne

  • 1*Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbus Drive, South, Suite 410, Tampa, FL 33606, USA. rhauser@hsc.usf.edu

Current Treatment Options in Neurology
|October 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autonomic Nervous System Dysfunction in Parkinson's Disease.

Current treatment options in neurology·2003
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Diffuse Lewy body disease (DLB) treatment focuses on managing dementia, hallucinations, and parkinsonism. Cholinesterase inhibitors are first-line for cognitive and psychiatric symptoms, while levodopa treats parkinsonism, avoiding worsening hallucinations.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Diffuse Lewy body disease (DLB) is a common neurodegenerative dementia.
  • It presents with cognitive decline, hallucinations, and parkinsonism.
  • Accurate diagnosis is crucial for effective management.

Purpose of the Study:

  • To outline current treatment strategies for Diffuse Lewy body disease.
  • To highlight the importance of tailored therapies for DLB symptoms.
  • To emphasize medication sensitivities in DLB patients.

Main Methods:

  • Review of existing literature on DLB treatment.
  • Analysis of therapeutic options for cognitive, psychiatric, and motor symptoms.
  • Discussion of medication risks and benefits in DLB.

Related Experiment Videos

Main Results:

  • Cholinesterase inhibitors (e.g., rivastigmine) are first-line for cognitive and neuropsychiatric symptoms.
  • Levodopa is preferred for parkinsonism, with caution due to potential hallucinations.
  • Atypical neuroleptics (e.g., quetiapine) may be used cautiously for behavioral disturbances.
  • Rapid eye movement sleep behavior disorder (RBD) can be managed with clonazepam or cholinergic agents.

Conclusions:

  • DLB management requires a multi-faceted approach targeting specific symptoms.
  • Cholinesterase inhibitors offer a favorable risk-benefit profile for core DLB symptoms.
  • Careful medication selection is vital due to heightened sensitivity in DLB patients.